Payment overview · 2025
General Payments
$837.14
43 reported records · 16 companies
Healthcare provider profile · identity verified
Ellen Vitievsky
Allopathic & Osteopathic Physicians|Internal Medicine · WEST NEW YORK, NJ · NPI 1366547135
Verified facts
What the public records show
CMS Open Payments records show Ellen Vitievsky received $837.14 in general payments during 2025 across 43 reported records.
Novo Nordisk Inc accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess, Otezla, Ozempic, Prolia, Rybelsus, Trelegy Ellipta, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ztlido by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $195.94 | 23.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $159.59 | 19.1% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.37 | 7.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $62.36 | 7.5% | 4 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $60.64 | 7.2% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $56.39 | 6.7% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $41.68 | 5.0% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $35.91 | 4.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.57 | 3.8% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $23.70 | 2.8% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $20.26 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.29 | 2.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.01 | 2.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.99 | 2.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.76 | 2.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.68 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $794.64 | 42 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $129.67 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $129.67 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.52 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $65.37 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $65.37 | 4 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $60.64 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $56.39 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.32 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $41.68 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $35.91 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $31.57 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.92 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 73 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 120 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 26 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
120 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
26 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
24 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
75 | 21 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 511 | 138 |
| Diclofenac Sodium | Diclofenac Sodium | 360 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 333 | 93 |
| Ammonium Lactate | Ammonium Lactate | 327 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 319 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 70 |
| Gabapentin | Gabapentin | 257 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 219 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 58 |
| Alendronate Sodium | Alendronate Sodium | 212 | 56 |
| Meclizine Hcl | Meclizine Hcl | 211 | 47 |
| Ezetimibe | Ezetimibe | 208 | 54 |
| Omeprazole | Omeprazole | 205 | 56 |
| Losartan Potassium | Losartan Potassium | 191 | 55 |
| Vascepa | Icosapent Ethyl | 172 | 44 |
| Ibandronate Sodium | Ibandronate Sodium | 161 | 36 |
| Lidocaine | Lidocaine | 160 | 29 |
| Allopurinol | Allopurinol | 159 | 29 |
| Januvia | Sitagliptin Phosphate | 155 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 149 | 29 |
| Montelukast Sodium | Montelukast Sodium | 140 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 135 | 20 |
| Metformin Hcl | Metformin Hcl | 128 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 36 |
| Memantine Hcl | Memantine Hcl | 124 | 23 |
| Alprazolam | Alprazolam | 123 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 32 |
| Linzess | Linaclotide | 120 | 27 |
| Baclofen | Baclofen | 117 | 40 |
| Mirtazapine | Mirtazapine | 117 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 26 |
| Pregabalin | Pregabalin | 112 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 111 | 25 |
| Ketoconazole | Ketoconazole | 107 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 27 |
| Lisinopril | Lisinopril | 105 | 28 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 103 | 19 |
| Eliquis | Apixaban | 103 | 25 |
| Glimepiride | Glimepiride | 103 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 99 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 20 |
| Famotidine | Famotidine | 95 | 23 |
| Furosemide | Furosemide | 91 | 20 |
| Ozempic | Semaglutide | 91 | 24 |
| Hydrocortisone | Hydrocortisone | 85 | 15 |
| Trazodone Hcl | Trazodone Hcl | 84 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 81 | 25 |
| Mometasone Furoate | Mometasone Furoate | 78 | 30 |
| Sertraline Hcl | Sertraline Hcl | 78 | 17 |
| Azithromycin | Azithromycin | 75 | 58 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 14 |
| Ztlido | Lidocaine | 75 | 21 |
| Mounjaro | Tirzepatide | 74 | suppressed |
| Creon | Lipase/Protease/Amylase | 73 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 73 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 72 | 15 |
| Methylprednisolone | Methylprednisolone | 71 | 56 |
| Atenolol | Atenolol | 70 | 16 |
| Farxiga | Dapagliflozin Propanediol | 67 | 13 |
| Azelastine Hcl | Azelastine Hcl | 65 | 12 |
| Jardiance | Empagliflozin | 62 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 12 |
| Repaglinide | Repaglinide | 62 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | 29 |
| Donepezil Hcl | Donepezil Hcl | 59 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 57 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 15 |
| Trulicity | Dulaglutide | 57 | 12 |
| Meloxicam | Meloxicam | 56 | 20 |
| Valsartan | Valsartan | 56 | 13 |
| Amoxicillin | Amoxicillin | 55 | 51 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 55 | 16 |
| Eszopiclone | Eszopiclone | 55 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 55 | suppressed |
| Potassium Chloride | Potassium Chloride | 55 | suppressed |
| Carvedilol | Carvedilol | 52 | 14 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 52 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 52 | 11 |
| Nystatin | Nystatin | 51 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 51 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 47 | 14 |
| Lubiprostone | Lubiprostone | 46 | suppressed |
| Clonazepam | Clonazepam | 45 | 13 |
| Procto-Med Hc | Hydrocortisone | 45 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 12 |
| Naproxen | Naproxen | 42 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 40 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | 11 |
| Restasis | Cyclosporine | 39 | suppressed |
| Myrbetriq | Mirabegron | 38 | 12 |
| Ranolazine Er | Ranolazine | 38 | suppressed |
| Trulance | Plecanatide | 38 | 12 |
| Mupirocin | Mupirocin | 37 | 25 |
| Spiriva Respimat | Tiotropium Bromide | 37 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 34 | 14 |
| Rivastigmine | Rivastigmine | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 33 | suppressed |
| Zaleplon | Zaleplon | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 31 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Prednisone | Prednisone | 29 | 20 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 16 |
| Dexamethasone | Dexamethasone | 26 | 22 |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Prolia | Denosumab | 26 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 25 | 19 |
| Risedronate Sodium | Risedronate Sodium | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Ciclopirox | Ciclopirox | 24 | suppressed |
| Edarbi | Azilsartan Medoxomil | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 15 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Desloratadine | Desloratadine | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Nateglinide | Nateglinide | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 19 |
| Topiramate | Topiramate | 20 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Dexilant | Dexlansoprazole | 17 | suppressed |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 17 | suppressed |
| Xiidra | Lifitegrast | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Maxalt | Rizatriptan Benzoate | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Alclometasone Dipropionate | Alclometasone Dipropionate | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clindamycin-Benzoyl Peroxide | Clindamycin Phos/Benzoyl Perox | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Horizant | Gabapentin Enacarbil | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Ergotamine-Caffeine | Ergotamine Tartrate/Caffeine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Klonopin | Clonazepam | 11 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Soma | Carisoprodol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $837.14 · 43 records | Novo Nordisk Inc | AFREZZA, AIRSUPRA, BREZTRI, CREON, EVENITY, GATTEX, GVOKE HYPOPEN, Hillrom - Monarch Airway Clearance System, IBSRELA, JARDIANCE, Kerendia, LINZESS, NEXLETOL, OTEZLA, Ohtuvayre, Ozempic, PROLIA, REPATHA, Rybelsus, TRELEGY ELLIPTA, ZORYVE, ZTLido | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error